Inhibition of B-16 melanoma growth in vitro by prostaglandin D2.

Abstract

Prostaglandin D2 was found to be a potent inhibitor of B-16 melanoma cell replication in vitro. The inhibition was dose-dependent between 3x10(-9)M and 3x10(-6)M (IC50 approximately 0.3 microM after 6 days). On a molar basis, PGD2 was a better inhibitor than PGA2 or 16, 16-dimethyl-PGE2-methyl ester (di-M-PGE2) and in higher concentrations (10(-6)-10(-7)M), comparable to retinoic acid. In higher concentrations, PGD2 inhibited DNA, RNA and protein synthesis. The B-16 melanoma cell line which we used synthesized arachidonic acid metabolites which comigrated with PGA2, PGD2, PGE2, and PGF2 alpha on a thin layer chromatography system.

• Authors: T Simmet, B M Jaffe
• Journal: Prostaglandins (Prostaglandins) Vol. 25 Issue 1 Pg. 47-54 (Jan 1983) ISSN: 0090-6980 [Print] United States
• PMID: 6573723 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• DNA, Neoplasm
• Neoplasm Proteins
• Oleic Acids
• Prostaglandins
• Prostaglandins D
• RNA, Neoplasm
• Oleic Acid
• Prostaglandin D2

Topics

• Animals
• Antineoplastic Agents
• Cells, Cultured
• DNA, Neoplasm (biosynthesis)
• Female
• Humans
• Melanoma (metabolism)
• Mice
• Mice, Inbred C57BL
• Neoplasm Proteins (biosynthesis)
• Neoplasms, Experimental (metabolism)
• Oleic Acid
• Oleic Acids (metabolism)
• Prostaglandin D2
• Prostaglandins (pharmacology)
• Prostaglandins D (pharmacology)
• RNA, Neoplasm (biosynthesis)
• Time Factors